Archive:
Feb 11, 2025, 12:00 AM
Melanoma patients receiving combination anti-PD-1/CTLA-4 immunotherapy have greater longterm risk of neurologic immune-related adverse events than patients receiving anti-PD-1 monotherapy
Background: Over the past decade, novel immune checkpoint inhibitors have revolutionized melanoma treatment. These new therapies are associated with complex immune-related adverse events. This study e…
Tumor infiltrating lymphocytes in primary melanoma associated with better prognosis
Background: The relationship between tumor infiltrating lymphocytes (TIL) and survival in melanoma is poorly understood. We present a large multicenter study assessing the association between TIL and …